Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities

Shetty, Manasa Gangadhar; Pai, Padmini; Bipasa Dey; Satyamoorthy K.; Suranjan Shil; Nayak, Usha Yogendra; Ashwini T.; Babitha Kampa Sundara

dc.contributor.author	Shetty, Manasa Gangadhar
dc.contributor.author	Pai, Padmini
dc.contributor.author	Bipasa Dey
dc.contributor.author	Satyamoorthy K.
dc.contributor.author	Suranjan Shil
dc.contributor.author	Nayak, Usha Yogendra
dc.contributor.author	Ashwini T.
dc.contributor.author	Babitha Kampa Sundara
dc.date.accessioned	2025-01-26T05:12:35Z
dc.date.available	2025-01-26T05:12:35Z
dc.date.issued	2024-06
dc.identifier.citation	Daru. 2024 June; 32(1): 263-278.	en_US
dc.identifier.issn	1560-8115
dc.identifier.uri	http://dspace.sdmucmsh.edu.in:8080/xmlui/handle/123456789/2403
dc.language.iso	en	en_US
dc.publisher	Springer International Publishing	en_US
dc.subject	1,10-Phenanthroline	en_US
dc.subject	Hydroxamic acid	en_US
dc.subject	HDAC	en_US
dc.subject	RR	en_US
dc.subject	Anti-cancer	en_US
dc.subject	Dual targeting	en_US
dc.title	Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities	en_US
dc.type	Article	en_US